Samjong KPMG Delivers Lecture on Accounting and Tax at '2025 Pharmaceutical and Bio Seminar'

Discussion on Risks and Response Strategies

Samjong KPMG announced on the 4th that it delivered a lecture on accounting and tax issues in the pharmaceutical and bio industry at a seminar hosted by the Korea Pharmaceutical and Bio-Pharma Manufacturers Association on the 3rd.

Samjong KPMG is giving a lecture at the "Pharmaceutical Bio Accounting and Tax Issues Seminar" hosted by the Korea Pharmaceutical and Bio-Pharma Manufacturers Association on the 3rd. Samjong KPMG

This seminar was organized to enhance accounting transparency and tax risk management capabilities within the pharmaceutical and bio industry. In response to rapid changes in the global pharmaceutical environment, such as the introduction of artificial intelligence (AI) and the strengthening of tax audits, the event featured practical discussions to address industry-wide transformations. More than 200 industry professionals attended.

In the first session, Park Sanghoon, Executive Director, and Kim Suyeon, Director at Samjong KPMG, gave a presentation on "Recent Trends in Accounting and Financial Closing." The presentation focused on major accounting issues and the impact of amendments to the Commercial Act on companies, highlighting: ▲Analysis of review findings and key inspection items by the Financial Supervisory Service ▲Financial risks and accounting treatment related to Contract Sales Organizations (CSO) ▲Disclosure measures for internal control over funds in the internal accounting management system.

Next, Executive Director Cho Yongho of Samjong KPMG introduced methods to enhance the efficiency of financial work and automate closing processes using AI. He stated, "AI-based data analysis is a key tool for simplifying the closing process and improving the reliability of financial information," and predicted, "AI technology will continue to expand across all areas of accounting and finance."

Executive Directors Choi Eunyeong and Jeong Pilgwang of Samjong KPMG led a session on "Trends and Implications of Tax Audits in the Pharmaceutical and Bio Industry." They analyzed case studies of frequently occurring tax audit issues in the pharmaceutical and bio sectors and presented tax law amendments and response strategies applicable to pharmaceutical and bio companies.

Park Sanghoon, Executive Director and leader of the KPMG Korea Life Science sector, stated, "The accounting and tax environment of the pharmaceutical and bio industry is rapidly changing due to the spread of AI and digital technologies, as well as the strengthening of global regulations." He added, "Samjong KPMG will provide practical, customized consulting and sustainable growth strategies based on a professional understanding of the industry’s unique characteristics and regulatory structure."